Germany - German - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

aristo pharma gmbh (3082323) - buprenorphin - transdermales pflaster - 30 mikrogamm/stunde - teil 1 - transdermales pflaster; buprenorphin (20180) 30 milligramm

Germany - German - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

aristo pharma gmbh (3082323) - buprenorphin - transdermales pflaster - 40 mikrogamm/stunde - teil 1 - transdermales pflaster; buprenorphin (20180) 40 milligramm

Netherlands - Dutch - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

eureco-pharma b.v. - fluvoxaminewaterstofmaleaat samenstelling overeenkomend met; fluvoxamine; - filmomhulde tablet - fluvoxamine

Netherlands - Dutch - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

eureco-pharma b.v. - fluvoxaminewaterstofmaleaat samenstelling overeenkomend met; fluvoxamine; - filmomhulde tablet - fluvoxamine

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

dafra pharma gmbh - amoxicillin 200mg,clavulanic acid 28mg - dafraclav® is indicated in the treatment of the following in­fections caused by the microorganisms indicated below. upper respiratory tract infections (including otitis media and sinusitis), due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. lower respiratory tract infections, due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. skin and skin structure infections, due to beta-lactamase producing strains of staphylococcus aureus, escherichia coli and klebsiella spp. urinary tract infections. since dafraclav® contains amoxicillin, it can be used in the treatment of infections caused by bacteria susceptible to ampicillin. additionally, if in a mixed infection a microorganisms is susceptible to ampicillin and the other which is a beta-lactamase producer is susceptible to dafraclav®, such an infection can be treated by the administration of dafraclav® alone, addition of another antibiotic is not required.

European Union - English - EMA (European Medicines Agency)

merz pharmaceuticals gmbh - memantine hydrochloride - alzheimer disease - other anti-dementia drugs - treatment of patients with moderate to severe alzheimer's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - moclobemide, quantity: 150 mg - tablet, film coated - excipient ingredients: dextrates; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; hypromellose; polydextrose; macrogol 3350; titanium dioxide; iron oxide yellow; carnauba wax - treatment of major depression.

Egypt - English - EDA (Egyptian Drug Authority)

lmco pharm - tylosin tartarate 541 mg ( eq. to tylosin base 500 mg) +oxytetracycline hcl 216 mg (eq. to oxytetracycline base 200 mg) /1gm - water soluble powder

Egypt - English - EDA (Egyptian Drug Authority)

lmco pharm -

Egypt - English - EDA (Egyptian Drug Authority)

lmco pharma - sulphadimidine sodium 87.6 gm ( eq.to sulphadimidine base 80 gm) + diaverdine 2.5 gm + vitamin k3 3 gm /100gm - injectable solution